{"hands_on_practices": [{"introduction": "Understanding antibiotic resistance begins with recognizing that some bacteria are naturally immune to certain drugs due to their fundamental structure. This phenomenon, known as intrinsic resistance, is a critical factor in clinical decision-making. The following thought experiment [@problem_id:2279461] challenges you to apply your knowledge of bacterial cell anatomy to explain why a powerful antibiotic effective against one major class of bacteria is useless against another, highlighting how physical barriers can be the first and most effective line of defense.", "problem": "Vancomycin is a large glycopeptide antibiotic crucial for treating infections caused by certain Gram-positive bacteria. Its mechanism of action involves binding to the D-Alanine-D-Alanine (D-Ala-D-Ala) termini of peptidoglycan precursors, thereby inhibiting the cross-linking step of cell wall synthesis. However, vancomycin is generally ineffective against most Gram-negative bacteria, a phenomenon referred to as intrinsic resistance.\n\nConsidering the fundamental structural differences between Gram-positive and Gram-negative bacteria, what is the primary reason for this intrinsic resistance, even when the Gram-negative bacterium possesses no specific, genetically-encoded resistance mechanism such as an efflux pump or target-modifying enzyme?\n\nA. Gram-negative bacteria lack a peptidoglycan layer entirely, so vancomycin has no target.\n\nB. The outer membrane of Gram-negative bacteria acts as a physical barrier, preventing the large vancomycin molecule from reaching its target in the periplasmic space.\n\nC. Gram-negative bacteria possess a unique set of constitutively active efflux pumps that are part of their core genome and effectively remove vancomycin before it can act.\n\nD. The ribosomes of Gram-negative bacteria have a different structure that is not susceptible to binding by vancomycin.\n\nE. The peptidoglycan precursors in all Gram-negative bacteria are naturally modified to a D-Alanine-D-Lactate structure, which has a low affinity for vancomycin.", "solution": "Vancomycin’s mechanism requires access to its target: the D-Alanine-D-Alanine termini of peptidoglycan precursors (e.g., lipid II) located where peptidoglycan synthesis occurs. In Gram-positive bacteria, there is no outer membrane; the thick peptidoglycan layer is externally accessible, allowing vancomycin to bind its target and inhibit transglycosylation and transpeptidation steps of cell wall synthesis.\n\nIn contrast, Gram-negative bacteria possess a fundamentally different cell envelope architecture: an outer membrane external to a thin peptidoglycan layer located in the periplasmic space. The outer membrane, composed of lipopolysaccharide in the outer leaflet and phospholipids in the inner leaflet, serves as a permeability barrier. Entry of hydrophilic solutes into the periplasm occurs mainly through porins, which impose size and charge selectivity. Vancomycin is a large glycopeptide molecule, and its size prevents efficient transit through typical Gram-negative porins. Thus, even in the absence of specialized resistance determinants such as efflux pumps or target-modifying enzymes, vancomycin cannot reach its periplasmic target in Gram-negative bacteria.\n\nEliminating the incorrect options:\n- A is incorrect because Gram-negative bacteria do possess peptidoglycan, albeit a thinner layer, located in the periplasm.\n- C is not the primary reason and is excluded by the premise that no specific genetically encoded resistance (such as efflux) is present.\n- D is incorrect because vancomycin does not target ribosomes; it targets cell wall precursors.\n- E is incorrect because the D-Alanine-D-Lactate modification is an acquired resistance mechanism (classically in some Gram-positive enterococci via van genes), not an intrinsic universal feature of Gram-negative bacteria.\n\nTherefore, the primary reason for intrinsic resistance is the outer membrane barrier preventing vancomycin from accessing its periplasmic target.", "answer": "$$\\boxed{B}$$", "id": "2279461"}, {"introduction": "When bacteria acquire resistance genes, often on mobile genetic elements like plasmids, the resulting level of protection can vary dramatically. It's not simply a matter of presence or absence of a gene; the quantity of the resistance protein produced plays a crucial role. This exercise [@problem_id:2279422] explores the concept of gene dosage, demonstrating how the copy number of a plasmid can directly determine the degree of antibiotic resistance, a principle that has significant implications for the evolution and spread of highly resistant strains.", "problem": "In a molecular biology laboratory, a researcher is studying antibiotic resistance in *Escherichia coli*. Two strains of *E. coli*, Strain X and Strain Y, are used. Both strains are initially sensitive to the antibiotic ampicillin. Ampicillin resistance is often conferred by the *bla* gene, which codes for the enzyme beta-lactamase. This enzyme inactivates ampicillin by hydrolyzing its beta-lactam ring.\n\nThe researcher transforms both strains with plasmids carrying the exact same *bla* gene, including its promoter and other regulatory sequences. The only difference is the type of plasmid used:\n- Strain X is transformed with a high-copy-number plasmid, which replicates to maintain approximately 500 copies per cell.\n- Strain Y is transformed with a low-copy-number plasmid, which replicates to maintain approximately 10 copies per cell.\n\nAssuming all other conditions are identical (e.g., cell growth rate, nutrient availability, transformation efficiency) and that the production of beta-lactamase is not limited by other cellular resources, which of the following outcomes is most likely when both strains are grown on culture plates with a gradient of increasing ampicillin concentration?\n\nA. Strain X will be able to grow at higher ampicillin concentrations than Strain Y.\n\nB. Strain Y will be able to grow at higher ampicillin concentrations than Strain X.\n\nC. Both strains will show identical levels of resistance and grow up to the same ampicillin concentration.\n\nD. Neither strain will be effectively resistant because the metabolic load of the plasmids will weaken the cells.\n\nE. The level of resistance will be primarily determined by random mutations in the host chromosome, not the plasmids.", "solution": "Define $c_{X}$ and $c_{Y}$ as the plasmid copy numbers in Strain X and Strain Y, respectively, with $c_{X}>c_{Y}$ by the problem setup. Because the two plasmids carry the exact same $bla$ gene, promoter, and regulatory sequences, and the problem assumes that production of beta-lactamase is not limited by other cellular resources, the per-cell beta-lactamase level scales linearly with copy number. Let $\\alpha$ collect the effective transcription, translation, and protein stability factors (identical between strains). Then the steady-state enzyme levels satisfy\n$$\nE_{X}=\\alpha c_{X},\\quad E_{Y}=\\alpha c_{Y}.\n$$\nAmpicillin inactivation by beta-lactamase increases with enzyme amount. Let the effective detoxification capacity be $V_{\\text{detox}}=k E$, where $k$ is a proportionality constant capturing catalytic efficiency and antibiotic availability to the enzyme. Let the antibiotic influx scale with the external concentration as $J_{\\text{in}}=k_{\\text{in}}A_{\\text{ext}}$, where $k_{\\text{in}}$ is an effective influx constant and $A_{\\text{ext}}$ is the external ampicillin concentration. A sufficient condition for maintaining a non-inhibitory intracellular antibiotic level during growth is that detoxification capacity at least balances influx:\n$$\nV_{\\text{detox}}\\geq J_{\\text{in}}\\quad\\Longrightarrow\\quad kE\\geq k_{\\text{in}}A_{\\text{ext}}.\n$$\nThis yields a maximum external concentration compatible with growth,\n$$\nA_{\\text{ext,max}}=\\frac{k}{k_{\\text{in}}}E=\\frac{k}{k_{\\text{in}}}\\alpha c\\equiv \\beta c,\n$$\nwhere $\\beta=(k\\alpha)/k_{\\text{in}}$ is constant across strains under the stated assumptions. Therefore,\n$$\n\\frac{A_{\\text{ext,max},X}}{A_{\\text{ext,max},Y}}=\\frac{c_{X}}{c_{Y}}>1,\n$$\nso Strain X, with the higher copy number, achieves a higher beta-lactamase level and thus tolerates higher ampicillin concentrations than Strain Y. Options asserting identical resistance are inconsistent with $c_{X}\\neq c_{Y}$, metabolic-load failure is excluded by the assumption that production is not resource-limited, and random chromosomal mutations are not the primary determinant here since both strains receive the same resistance gene and conditions.", "answer": "$$\\boxed{A}$$", "id": "2279422"}, {"introduction": "One of the most direct forms of antibiotic resistance is for bacteria to produce enzymes that chemically attack and neutralize the drug. This practice problem [@problem_id:2279451] places you in a scenario where you can quantitatively model this process. By applying the principles of enzyme kinetics, you will calculate the time required for a resistant bacterial population to reduce an antibiotic's concentration to a non-lethal level, bridging the gap between molecular mechanisms and clinically relevant outcomes.", "problem": "A pathogenic bacterial strain, *Resistobacterium pharmacovorax*, has developed resistance to a novel antibiotic. The mechanism of resistance involves a periplasmic enzyme, which we will call Antibiotic Glycosylating Enzyme (AGE). This enzyme catalyzes the covalent attachment of a glucose molecule to the antibiotic, rendering it biologically inactive. A researcher prepares a liquid culture medium containing a high density of stationary-phase *R. pharmacovorax*, resulting in a constant and uniform concentration of the AGE enzyme in the medium.\n\nThe kinetics of the AGE enzyme with respect to the antibiotic as a substrate are characterized by a Michaelis constant, $K_M = 40.0 \\text{ µM}$, and a turnover number, $k_{cat} = 150 \\text{ s}^{-1}$. The total concentration of active AGE enzyme in the medium is constant at $[E]_T = 8.00 \\text{ nM}$.\n\nAt time $t=0$, the antibiotic is introduced into the medium to an initial concentration of $[A]_0 = 200.0 \\text{ µM}$. The bacteria can resume growth only when the concentration of the active antibiotic drops below its Minimum Inhibitory Concentration (MIC), which is $[A]_{MIC} = 5.00 \\text{ µM}$.\n\nAssuming the concentration of glucose is saturating and does not influence the reaction rate, calculate the time it will take for the concentration of the active antibiotic to be reduced to its MIC. Express your answer in seconds, rounded to three significant figures.", "solution": "The antibiotic $A$ is consumed by the AGE enzyme following Michaelis–Menten kinetics with constant enzyme concentration. The reaction rate for $A$ is\n$$\nv = \\frac{d[A]}{dt} = -\\frac{k_{cat}[E]_{T}[A]}{K_{M} + [A]}.\n$$\nSeparating variables and integrating from $[A](0) = [A]_{0}$ to $[A](t) = [A]_{MIC}$ gives\n$$\n\\int_{[A]_{0}}^{[A]_{MIC}} \\left(\\frac{K_{M}}{A} + 1\\right) dA = -k_{cat}[E]_{T} \\int_{0}^{t} dt,\n$$\nwhich evaluates to\n$$\nK_{M} \\ln\\!\\left(\\frac{[A]_{MIC}}{[A]_{0}}\\right) + \\left([A]_{MIC} - [A]_{0}\\right) = -k_{cat}[E]_{T} \\, t.\n$$\nSolving for $t$,\n$$\nt = \\frac{K_{M} \\ln\\!\\left(\\frac{[A]_{0}}{[A]_{MIC}}\\right) + \\left([A]_{0} - [A]_{MIC}\\right)}{k_{cat}[E]_{T}}.\n$$\nUse consistent units in micromolar for concentrations. Convert $[E]_{T} = 8.00 \\text{ nM} = 0.00800 \\text{ µM}$, and take $K_{M} = 40.0 \\text{ µM}$, $[A]_{0} = 200.0 \\text{ µM}$, $[A]_{MIC} = 5.00 \\text{ µM}$, $k_{cat} = 150 \\text{ s}^{-1}$. Then\n$$\nt = \\frac{40.0 \\,\\ln\\!\\left(\\frac{200.0}{5.00}\\right) + \\left(200.0 - 5.00\\right)}{150 \\times 0.00800}\n= \\frac{40.0 \\,\\ln(40) + 195.0}{1.200}.\n$$\nCompute $\\ln(40) = 3.688879454$, so\n$$\nt = \\frac{40.0 \\times 3.688879454 + 195.0}{1.200}\n= \\frac{147.5551782 + 195.0}{1.200}\n= \\frac{342.5551782}{1.200}\n= 285.4626485 \\text{ s}.\n$$\nRounded to three significant figures, the time is $285 \\text{ s}$.", "answer": "$$\\boxed{285}$$", "id": "2279451"}]}